The HealthHIV HIV Treatment Innovation Certificate Program is a CME/CE multi-module educational certificate program that will prepare providers already providing HIV care/treatment to treat more complex patient cases. Upon completion of the self-paced program, providers will earn an HIV Treatment Innovation Certificate which demonstrates competency in innovative, multi-level treatment optimization strategies for providing care and treatment to PWH.

Participants who complete the certificate program will have an understanding of current antiretroviral (ARV) therapies for optimal HIV treatment, the provider’s role in managing common co-infections and opportunistic infections, treatment optimization strategies to providing care through status-neutral-navigation, clinical guidelines to treating PWH in key populations, and a framework for managing treatment-experienced patients with HIV.

Target Audience This activity is intended for HIV care providers, primary care providers and general practitioners (includes MD/DO, NP, PA), nurses, pharmacists, patients/caregivers, and other professionals involved in the care of patients with HIV.  
  • Media: Enduring Material
  • Release date: October 31, 2023
  • Expiration date: October 30, 2024
  • Time to Complete: 30-60 minutes
  • Educational Objectives

    After completing this activity, the participant should be better able to:

    • Deliver comprehensive HIV care, including diagnosis, treatment, and management of antiviral resistance and common coinfections
    • Recognize the benefits and flexibility of currently available regimens for vulnerable populations living with HIV, including older adults
    • Apply individualized therapy for patients living with HIV that is based on novel and emerging strategies and addresses the diverse needs and preferences of individual patients (eg, adolescents, pregnant persons, those aged >65 years, unstably housed individuals, and those with substance use disorders) to promote health equity across the lifespan
    • Describe innovative approaches in HIV treatment and cure therapy
    Program Agenda
    • Module 1: Review of ARV Therapies to Optimize HIV Treatment
    • Module 2: Management of Common Co-Infections and Opportunistic Infections for People with HIV
    • Module 3: Considerations in the Management of HIV in Older Adults
    • Module 4: Emerging HIV Treatment Optimization Strategies for Key Populations
    • Module 5: Management of Treatment-Experienced Patients with HIV Drug Resistance

    Accreditation, Credit, and Support

    Round MLI logoHealthHIV logoAll modules are certified and participants can earn up to 5 Credits/Contact Hours (CME, MOC, NCPD, CPE, AAPA) for completion of the certificate.

    Joint accreditation logoIn support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and HealthHIV.  Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This program is supported by an independent educational grant from Gilead Sciences, Inc. 

    Physician Continuing Medical Education Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™ per module. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    MOC Statement Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

    ECMEC® Credit The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™ into European CME credit (ECMEC®) should contact the UEMS (

    Physician Associate Credit Designation Statement Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 30, 2024. PAs should only claim credit commensurate with the extent of their participation.

    Nursing Continuing Professional Development Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour. Please see below for the assigned pharmacology contact hour per module:

    Continuing Pharmacy Education

    Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. Type of Activity: Knowledge. Please see below for UAN numbers assigned to each module:

    Interprofessional Continuing Education (IPCE) Statement This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
    Planning Committee and Content/Peer Reviewers The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and HealthHIV, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies.
    Disclosure of Unlabeled Use This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Method of Participation There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on If you have questions regarding your certificate, please contact Beth via email at For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board. For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit (75% is required for ABS). For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website:

    About This Activity Medical Learning Institute, Inc. and HealthHIV are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and HealthHIV. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

    Faculty: Donna Sweet, MD, MACP, AAHIVS

    Course Description

    This course provides an overview of ARV therapies for optimal HIV treatment in primary care and HIV care settings.

    Educational Objectives

    ​​Upon completion of this activity, participants should be able to:

    • Describe current HIV treatment guidelines and recent updates, including key considerations for optimal HIV treatment in primary care and HIV care settings.

    • Explain the process of early treatment start/rapid start protocols, outlining the steps involved and the rationale for initiating antiretroviral therapy promptly.

    • Identify recommendations on first-line and second-line antiretroviral regimens

    • Discuss laboratory studies to obtain at baseline and while monitoring response to therapy

    Faculty: W. David Hardy, MD, AAHIVS

    Course Description

    This course provides considerations for managing common co-infections and opportunistic infections among PWH.

    Educational Objectives

    ​​Upon completion of this activity, participants should be able to:

    • Identify effective strategies for managing common co-infections among people with HIV, including HCV/HBV, STIs, COVID-19, and Mpox

    • Develop comprehensive management approaches for common opportunistic infections among PWH

    Faculty: Jonathan Appelbaum, MD, FACP, AAHIVS

    Course Description
    This course provides considerations for managing HIV care among older adults and long-term HIV survivors.

    Educational Objectives

    ​​Upon completion of this activity, participants should be able to:

    • Identify common comorbidities most prevalent in older adults with HIV, based on findings from the REPRIEVE study

    • Discuss strategies and special considerations for managing HIV care in older adults who did not initiate early start on treatment

    • Evaluate the potential impact of long-term antiretroviral therapy on cardiometabolic risk and other comorbidities in older adults and long-term HIV survivors

    • Develop strategies for managing both antiretroviral therapy and cardiometabolic risk factors in patients with HIV

    Faculty: Michelle S. Cespedes, MD, MS and Monica Gandhi, MD, MPH

    Course Description

    This course provides evidence-based HIV treatment optimization strategies for delivering quality HIV care among key populations.

    Educational Objectives

    ​​Upon completion of this activity, participants should be able to:

    • Discuss innovative medicines and treatment optimization strategies, including the use of long-acting injectable antiretroviral therapy (LAI-ART) injectables

    • Identify model practices for treating pregnant persons and patients with competing priorities (e.g. unstably housed, people with substance use disorders)

    • Develop HIV treatment optimization strategies via street medicine models and status neutral clinic models

    • Describe adverse effects of ART, including weight gain and metabolic effects, and ways to address these issues

    Faculty: Monica Gandhi, MD, MPH

    Course Description
    This course provides information on the latest strategies for managing treatment of patients with HIV drug resistance.

    Educational Objectives

    ​​Upon completion of this activity, participants should be able to:

    • Identify impacts of HIV drug resistance on patients and communities

    • Identify the causes of virologic failure and methods to assess virologic failure and HIV drug resistance

    • Identify steps for constructing new treatment regimens for patients with HIV drug resistance

    • Identify considerations for special populations with HIV drug resistance

    After completion of all five modules, please select to receive your final certificate.